-logo.jpg "Veru logo")
Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Phone305-509-6897
Debt
Current Ratio0.83
Quick Ratio0.66
Price-To-Earnings
Sales & Book Value
Annual Sales$15.86 million
Price / Sales5.49
Price / Cash FlowN/A
Price / Book2.62
Profitability
Net Income$-23,930,000.00
Net Margins-150.89%
Return on Assets-40.67%
Miscellaneous
Employees171
OptionableOptionable
Veru (NASDAQ:VERU) Frequently Asked Questions
What is Veru's stock symbol?
Veru trades on the NASDAQ under the ticker symbol "VERU."
How were Veru's earnings last quarter?
Veru Inc (NASDAQ:VERU) announced its quarterly earnings data on Thursday, December, 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.05. The business had revenue of $5.20 million for the quarter, compared to the consensus estimate of $7.25 million. Veru had a negative net margin of 150.89% and a negative return on equity of 56.71%. View Veru's Earnings History.
When is Veru's next earnings date?
What price target have analysts set for VERU?
3 equities research analysts have issued twelve-month price targets for Veru's shares. Their predictions range from $5.00 to $10.00. On average, they expect Veru's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 439.6% from the stock's current price. View Analyst Price Targets for Veru.
What is the consensus analysts' recommendation for Veru?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.
What are Wall Street analysts saying about Veru stock?
Here are some recent quotes from research analysts about Veru stock:
- 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (10/17/2018)
- 2. Maxim Group analysts commented, "Veru announced the company was awarded 75% of the South Africa female condom tender, or a total of 120M female condoms over three years. We view this news as a significant positive, as it will continue to help offset the R&D burn associated with the urology pipeline, which is where we see the most significant value and upside in Veru." (8/27/2018)
- 3. HC Wainwright analysts commented, "Valuation methodology. Our price target is derived from a market value of the firm at $302M, which includes a discounted cash flow-based asset value of $313M for DRS, excluding $10.7M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS. Risks include, but are not limited to: (1) failure of FC2 or Tamsulosin DRS to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of Tamsulosin DRS in clinical trials; (3) clinical trial failures with other pipeline candidates; and (4) potential dilution risk." (8/15/2018)
Has Veru been receiving favorable news coverage?
Headlines about VERU stock have been trending positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veru earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of Veru's key competitors?
Some companies that are related to Veru include Fluidigm (FLDM), GenMark Diagnostics (GNMK), Avrobio (AVRO), Abeona Therapeutics (ABEO), Merus (MRUS), Five Prime Therapeutics (FPRX), Replimune Group (REPL), Insys Therapeutics (INSY), Concert Pharmaceuticals (CNCE), Cellular Biomedicine Group (CBMG), ZIOPHARM Oncology (ZIOP), MiMedx Group (MDXG), Utah Medical Products (UTMD), Dermira (DERM) and Lannett (LCI).
Who are Veru's key executives?
Veru's management team includes the folowing people:
- Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 57)
- Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 59)
- Mr. O. B. Parrish, Co-Founder & Director (Age 85)
- Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)
- Dr. K. Gary Barnette, Chief Scientific Officer
How do I buy shares of Veru?
Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veru's stock price today?
One share of VERU stock can currently be purchased for approximately $1.39.
How big of a company is Veru?
Veru has a market capitalization of $85.16 million and generates $15.86 million in revenue each year. The company earns $-23,930,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Veru employs 171 workers across the globe.
What is Veru's official website?
How can I contact Veru?
Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]
MarketBeat Community Rating for Veru (NASDAQ VERU)
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
